Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

PAK (polyester alkyd)/ imidazoline/RGD (arginine-glycine-aspartic acid) ternary conjugate and preparation method and use thereof

A technology of tetramethylimidazoline and compounds, which is applied in the field of PAK/imidazoline/RGD ternary conjugates and their preparation and application, can solve the problem of inability to effectively cross the blood-brain barrier, complex and limited curative effect of patients with cerebral infarction to achieve excellent anti-stroke activity, protect neurological function, and reduce the volume of cerebral infarction

Inactive Publication Date: 2013-01-23
YONG GUANG PHARMA
View PDF0 Cites 33 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the problems faced by the treatment of cerebral infarction are more complicated
For example, none of the existing thrombolytic drugs can effectively cross the blood-brain barrier, so that the curative effect of intravenous thrombolytic drugs on patients with cerebral infarction is extremely limited
Another example is that there is currently no suitable operation to treat patients with cerebral infarction

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • PAK (polyester alkyd)/ imidazoline/RGD (arginine-glycine-aspartic acid) ternary conjugate and preparation method and use thereof
  • PAK (polyester alkyd)/ imidazoline/RGD (arginine-glycine-aspartic acid) ternary conjugate and preparation method and use thereof
  • PAK (polyester alkyd)/ imidazoline/RGD (arginine-glycine-aspartic acid) ternary conjugate and preparation method and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Embodiment 1 prepares 2,3-dimethyl-2,3-dinitrobutane

[0037] 69g (0.78mol) of 2-nitropropane was added to 130ml of NaOH (6N) aqueous solution, and 20ml (0.38mol) of Br 2 , Added dropwise within 1 hour, then added 240ml of ethanol, refluxed at 90°C for 3h, poured the reaction solution into 800ml of ice water while heating, and filtered 55g (81%) of the title compound as colorless flaky crystals, Mp110-112°C.

Embodiment 2

[0038] Embodiment 2 prepares 2,3-dimethyl-2,3-dihydroxyaminobutane

[0039] 7g (40mmol) 2,3-dimethyl-2,3-dinitrobutane and 4g NH 4 Cl was suspended in 80ml ethanol aqueous solution (50%), stirred under ice bath, and 16g zinc powder was added within 3h. After the zinc powder was added, the ice bath was removed, and the stirring reaction at room temperature was continued for 3 h, and then the reaction liquid was suction-filtered. The filter cake was washed repeatedly with aqueous ethanol (50%), the filtrate and washings were combined, adjusted to pH = 2 with concentrated hydrochloric acid, and steamed under reduced pressure until it became a slurry. Add an appropriate amount of potassium carbonate, mix well, use a Soxhlet extractor, use chloroform as the extractant, and extract for 6 hours. The extract is concentrated under reduced pressure to a small amount. After adding petroleum ether, 2.60 g (44%) of the title compound is precipitated as colorless crystals . Mp157-159°C. ...

Embodiment 3

[0040] Example 3 Preparation of 1,3-dihydroxy-2-(4'-hydroxyphenyl)-4,4,5,5-tetramethylimidazolidine

[0041] 1.22g (10mmol) of p-hydroxybenzaldehyde and 1.48g (10mmol) of 2,3-dimethyl-2,3-dihydroxyaminobutane were dissolved in 10ml of methanol. After stirring at room temperature for 8h, TLC showed that the raw material point disappeared. Filtration with suction gave 1.29 g (51%) of the title compound as colorless crystals. EI-MS(m / z)252[M] + . 1 H-NMR (DMSO-d 6 )δ (ppm) = 1.03 (s, 6H), 1.05 (s, 6H), 4.39 (s, 1H), 6.70 (d, J = 6.9Hz, 2H), 7.23 (d, J = 6.9Hz, 2H) , 7.63(s, 1H), 7.85(s, 2H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a PAK(polyester alkyd) / imidazoline / RGD (arginine-glycine-aspartic acid) ternary conjugate and a preparation method and use of the PAK(polyester alkyd) / imidazoline / RGD (arginine-glycine-aspartic acid) ternary conjugate. The method comprises the steps of: taking L-Lys as a connection arm, and connecting 1, 3-dioxy-2-[(4-oxyacetic acid) phenyl]-4, 4, 5, 5-tetramethyl imidazoline, PAK tripeptide with thrombolytic effect, and RGD tetrapeptide with antithrombotic effect together to obtain PAK / imidazoline / RGD ternary complex integrated with three roles of striding blood brain barrier, dissolving thrombus and clearing NO into a whole shown in a formula 1. The PAK / imidazoline / RGD ternary complex disclosed by the invention has high activity of clearing NO free radical, excellent thrombolytic activity and antithrombotic activity. The internal anti-stroke activity proves that the PAK / imidazoline / RGD ternary conjugate can effectively protect a neurologic function of a stroke rat, reduces the cerebral infarction volume of the stoke rat, has the anti-stroke activity, and can be used as a clinical drug for treating cerebral infarction.

Description

technical field [0001] The present invention relates to ternary conjugates, in particular to 1-(4-oxoacetyl-phenyl)-3,3,4,4-tetramethyl-imidazoline, PAK tripeptide and RGD tetrapeptide via L- The ternary conjugate obtained by linking Lys together, the present invention also relates to the preparation method of the ternary conjugate, and the present invention further relates to the use of the ternary conjugate in removing NO, antithrombosis, thrombolysis and cerebral infarction treatment The medical use of the invention belongs to the field of PAK / imidazoline / RGD ternary conjugates and their medical use. Background technique [0002] Globally, thrombotic disease is the leading cause of morbidity and mortality. Coronary thrombosis, leading to myocardial infarction. Cerebrovascular embolism, leading to cerebral infarction. Patients with myocardial infarction can either receive intravenous thrombolytic drugs or undergo bypass surgery. It must be pointed out that the positive...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K7/06C07K1/06A61K38/08A61P7/02A61P39/06A61P9/10
CPCY02P20/55
Inventor 彭师奇赵明蒋雪云
Owner YONG GUANG PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com